Efficacy and Safety of Manidipine in Patients with Hypertension Aged 70 Years or Older

This study aimed to assess the efficacy and safety of manidipine in patients with hypertension aged 70 years or older. For this purpose, a 6-month study was performed. A total of 48 patients (mean age: 80.5 ± 7.1 years; 33.3% male) were included. The most common comorbidity was diabetes (39.6%). Manidipine 10 mg/day was prescribed in 72.9% of the patients and manidipine 20 mg/day in 27.1% of patients. Treatment with manidipine was associated with a significant decrease of blood pressure, from 163.3 ± 12.7/88.8 ± 9.6 mmHg to 147.8 ± 10.0/80.3 ± 6.4 mmHg (p < 0.01). Microalbuminuria was reduced from 27.1 to 8.3% during the study (p = 0.004). Barthel index and Get Up and Go test results remained unchanged, whilst there was a not significant improvement in the results from the Pfeiffer’s test. Manidipine administration was safe (only one patient left the study) and effective since blood pressure decreased significantly in a poorly controlled group of hypertensive patients (89% aged over 75 years and 58% aged over 80 years).